UK Eating Disorder services are facing unprecedented demand, with effective service delivery hampered by inadequate resources, fragmented services and variable care pathways. Individuals with eating disorders, families and clinicians all agree on the critical need to improve care pathways and treatment, leading to better outcomes.
Eating disorders are serious, complex conditions influenced by a blend of biological, psychological, and environmental factors. The approach of this project is grounded in the "biopsychosocial" model. Recently, anorexia research confirms a genetic component, with biological, metabolic, and psychological mechanisms at play. Further biological research across eating disorders could allow a better understanding of the mechanisms underlying eating disorder development and better, more personalised treatments.
This project will test the feasibility of establishing a UK-wide NHS research network spanning child and adult eating disorder services to enable a step change in the ability to conduct eating disorder research. It will help address fragmentation and facilitate novel biological, psychological, and social research collaborations. The data the investigators gather will be open to all researchers for data analyses, and the collaborations established will form a collaborative network to enable future clinical trials, experimental medicine and psychology.
The study will be conducted at child and adult eating disorder services who opt to join the Network. Participants will be patients receiving treatment for an eating disorder at one of the participating services, and their parents/guardians if applicable.
Participants will complete questionnaires and have blood and other physical tests as specified in the EDCRN dataset. The study will last until 29th October 2026 (the end of the current funding period) and/or when a participant is discharged from treatment, whichever is sooner. For participants discharged before the study ends, there will be an opportunity for patients to complete optional follow-up questionnaires on a periodic basis.

开始日期2024-10-01

申办/合作机构

King's College London

[+6]

NCT06452654 / Recruiting临床4期IIT

Anti-viral Action Against Type 1 Diabetes Autoimmunity

The study GPPAD-05 AVAnT1A is a phase 4 clinical trial intending to enroll 2252 children, who will be randomly assigned to receive COVID-19 vaccination (Comirnaty® 3 μg Omicron XBB.1.5 or new variant Comirnaty vaccines ) or placebo from age 6 months.
The study is an investigator initiated, randomized, controlled, multicentre, multinational, primary prevention trial for children at increased risk of type 1 diabetes.
The primary objective is to determine whether vaccination of children with elevated genetic risk for type 1 diabetes against COVID-19 from 6 months of age reduces the cumulative incidence of islet autoantibodies or type 1 diabetes in childhood.
Secondary objectives are:
1. to determine whether vaccination against COVID-19 similarly reduces the cumulative incidence of multiple islet autoantibodies in childhood.
2. to determine whether vaccination against COVID-19 similarly reduces the cumulative incidence of type 1 diabetes in childhood and
3. to determine whether vaccination against COVID-19 similarly reduces the cumulative incidence of celiac disease-associated transglutaminase autoantibodies in childhood.
Further exploratory objectives are described in the study protocol.
Study participants will be identified through an ongoing study screening for genetic risk of type 1 diabetes using a polygenic risk score (NCT03316261).
Eligible participants will be enrolled at age 3.00 to 4.00 months (baseline visit).
Randomization to vaccine or placebo will occur at age 6.00 to 7.00 months at visit 2. Consent will be obtained by the custodial parents prior to enrollment.

开始日期2024-05-08

申办/合作机构

Technische Universität München

[+6]

NCT06298292 / Not yet recruitingN/A

Zero Minis - Acceptability and Tolerance Market Research

The purpose of this prospective, observational study is to evaluate the tolerability and acceptability of Zero minis, a range of protein substitute tablets for use in the dietary management of children with either TYROSINAEMIA Type I, II, III or ALKAPTONURIA, HOMOCYSTINURIA, or MAPLE SYRUP URINE DISEASE (MSUD) over the age of 7 years.

开始日期2024-04-01

申办/合作机构

Birmingham Women's & Children's NHS Foundation Trust

[+1]

100 项与 Birmingham Women's & Children's NHS Foundation Trust 相关的临床结果

登录后查看更多信息

0 项与 Birmingham Women's & Children's NHS Foundation Trust 相关的专利（医药）

登录后查看更多信息

项与 Birmingham Women's & Children's NHS Foundation Trust 相关的新闻（医药）

2021-06-24

·MobiHealthNews

Nine NHS organisations selected to join Clinical Entrepreneur Programme

Sixty cross-sector partners have been selected to deliver the NHS Clinical Entrepreneur Programme, which aims to build economic growth in the science sector. Amongst these are NHS hospitals, multinational companies, research charities and business support networks. The programme was founded in 2016 with the goal of developing healthcare innovators in the UK to gain commercial skills, knowledge and experience to launch and deploy their business and innovation ideas. The following nine NHS organisations have been selected as partners to join the programme: Newcastle upon Tyne Hospitals NHS FT Hospitals Birmingham Women’s and Children’s Hospital NHS FT Bradford Teaching Hospitals NHS FT Mid and South Essex Hospitals Group Mid and South Essex NHS FT (MSEFT) Mid and South Essex Health and Care Partnership (MSE) Milton Keynes University Hospital Chelsea and Westminster Hospital NHS FT Northumbria Healthcare NHS FT WHY IT MATTERS The programme will provide opportunities for internships, access to NHS test and evaluation sites, academic and commercial facilities, access to funding, knowledge exchange and connection to customers. Since its inception, over 500 clinical entrepreneurs have been recruited, 247 life science startups have been launched and over £270 million of funding has been raised. Examples of innovations through the programme include smartphone otoscopes and drones designed to carry medical supplies between NHS sites. The NHS Clinical Entrepreneur Programme Partners include: JHUB Med BMJ Group – BMJ Ventures and BMJ innovation journal IBM Medtronic Olympus Unipart Minima Design FutureNova e-consult ORCHA Convenet Luminos Ventures Octopus Ventures GSK Deloitte Hughes Hall Cambridge Strathclyde University Pumping Marvellous Foundation National Voices Shuri network Generation Medics Health Careers Live Orthopaedic Research UK North of England Commissioning Support Unit (NECS) Shakespeare Martineau Oliver and Company MediLink Midlands Biocity Nestle THE LARGER CONTEXT Thirty-eight new AI projects have been announced as part of the NHS AI Lab's £140 million AI in Health and Care Awards. A share of £36 million to test AI technology has been invested in projects that aim to help the NHS transform the quality of care and the speed of diagnoses. In March, UK health secretary, Matt Hancock announced that a new wave of 30 trusts would join the Digital Aspirants Programme to boost their digital maturity and that seven trusts will receive up to £6 million over the next three years as part of the NHSX programme. ON THE RECORD Chris Chaney, chief executive of CW+, co-lead of the trust’s CW Innovation programme, said: “We are delighted to be a partner with the NHS Clinical Entrepreneur Programme and deliver on our shared vision to transform patient care and experience, as well as support our staff to innovate and bring new ideas to fruition. Our CW Innovation programme – jointly led by the Trust and its charity, CW+ – fast-tracks new technologies and innovations that address the most urgent and fundamental challenges faced by healthcare organisations today. “The COVID-19 pandemic has catalysed an acceleration in innovation and research and we have advanced at pace to introduce a range of innovations into the day-to-day running of our hospitals. Our collaboration with ARU and the NHS Clinical Entrepreneur Programme represents another exciting milestone for CW Innovation’s expanding portfolio of ‘test and scale’ partnerships that include digital healthcare, AI and machine learning, and remote patient-centred care.”

100 项与 Birmingham Women's & Children's NHS Foundation Trust 相关的药物交易

登录后查看更多信息

100 项与 Birmingham Women's & Children's NHS Foundation Trust 相关的转化医学

登录后查看更多信息